首页> 外文期刊>Advancements in Life Sciences >Comparative efficacy of different adjuvant containing inactivated vaccines against low-pathogenicity Avian Influenza H9N2 virus
【24h】

Comparative efficacy of different adjuvant containing inactivated vaccines against low-pathogenicity Avian Influenza H9N2 virus

机译:含不同佐剂的灭活疫苗对低致病性禽流感H9N2病毒的比较功效

获取原文
       

摘要

Background: Outbreaks of low-pathogenic Avian Influenza virus H9N2 (AIV-H9N2) occurred in poultry industry in Pakistan in 1998 and caused serious economic losses. Since then, many of the AIV-H9N2 vaccines have been introduced to Pakistani market to control the virus, however, it is still circulating all over the country. Therefore, the purpose of the study was to prepare and evaluate different adjuvant containing vaccines using local isolate of AIV-H9N2 in broiler birds. Methods: Three vaccines; Alum precipitated (AP-AIV), Aluminum hydroxide gel (AH-AIV) and Oil based (OB-AIV) were prepared in the laboratory and injected into broiler birds at 7th and 14th day of age. There were four groups of birds including one control group. To evaluate the serological response of the birds to vaccines, serum antibody titers were measured using haemagglutination inhibition test (HI). Vaccinated and control birds were challenged with AIV-H9N2 and virus shedding was determined from trachea and cloacal swabs by HI. Results: Out of the three prepared OB-AIV with hydrophile lypophile balance (HLB) values 5.37, 8.01 and 9.01, the vaccine with HLB value of 8.01 was the most stable. Each of the adjuvant containing vaccine was effective in inducing high HI antibody titers. However, OB-AIV was found to be the most effective in inducing a significantly higher (P 0.05) HI titer as compared to that of AP-AIV and AH-AIV each. No significant difference was observed between the HI titers induced by AP-AIV and AH-AIV. All the vaccines also showed effective protection against AIV-H9N2 challenge in vaccinated birds. Conclusion : In conclusion, this study reports the successful preparation and evaluation of adjuvant containing inactivated AIV-H9N2 vaccines. OB-AIV formulation was found to be most effective to control the H9N2 virus infections in broiler birds.
机译:背景:低致病性禽流感病毒H9N2(AIV-H9N2)爆发于1998年在巴基斯坦的家禽业中爆发,造成了严重的经济损失。从那时起,许多AIV-H9N2疫苗已被引入巴基斯坦市场以控制该病毒,然而,它仍在全国各地传播。因此,该研究的目的是使用肉鸡禽类的局部AIV-H9N2分离物来制备和评估不同的含佐剂疫苗。方法:三种疫苗;在实验室中准备了沉淀明矾(AP-AIV),氢氧化铝凝胶(AH-AIV)和油基(OB-AIV),并分别在第7 和第14 注入肉鸡天。有四组鸟类,包括一个对照组。为了评估禽类对疫苗的血清学反应,使用血凝抑制试验(HI)测量了血清抗体滴度。用AIV-H9N2攻击疫苗接种的鸟类和对照鸟类,并通过HI测定气管和泄殖腔拭子的病毒脱落。结果:在三种制备的亲水亲脂平衡值(HLB)为5.37、8.01和9.01的OB-AIV中,HLB值为8.01的疫苗最稳定。每种含佐剂的疫苗均有效诱导高HI抗体滴度。然而,与AP-AIV和AH-AIV相比,OB-AIV被发现最有效地诱导了明显更高的(P <0.05)HI滴度。在AP-AIV和AH-AIV诱导的HI滴度之间没有观察到显着差异。所有疫苗还显示出对接种禽类的AIV-H9N2攻击具有有效的保护作用。结论:总之,本研究报告了成功制备和评估含灭活AIV-H9N2疫苗的佐剂。发现OB-AIV制剂对控制肉鸡H9N2病毒感染最有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号